Updated Jul 16, 2026
Andrade Robert has filed 3 SEC Form 4 filings across 1 company in the last 90 days.
Robert Andrade is the Chief Financial Officer of Fennec Pharmaceuticals Inc., a biopharmaceutical company focused on developing treatments to prevent cisplatin-induced hearing loss in children. He has been involved in multiple SEC filings related to the company's financial activities.
| Role | Insider |
|---|---|
| Notability | 20/100 |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-07-01 | FENC | FENNEC PHARMACEUTICALS INC. | A — Grant or award | 1.7K | $0.00 | |
| 2026-06-01 | FENC | FENNEC PHARMACEUTICALS INC. | A — Grant or award | 1.7K | $0.00 | |
| 2026-05-01 | FENC | FENNEC PHARMACEUTICALS INC. | M — Option exercise | 1.7K | $0.00 | |
| 2026-04-02 | FENC | FENNEC PHARMACEUTICALS INC. | M — Option exercise | 12.3K | $0.00 | |
| 2026-04-02 | FENC | FENNEC PHARMACEUTICALS INC. | M — Option exercise | 2.2K | $0.00 | |
| 2026-04-02 | FENC | FENNEC PHARMACEUTICALS INC. | M — Option exercise | 14.7K | $0.00 | |
| 2026-03-26 | FENC | FENNEC PHARMACEUTICALS INC. | M — Option exercise | 13.1K | $5.10 | $67K |
| 2026-03-03 | FENC | FENNEC PHARMACEUTICALS INC. | A — Grant or award | 1.2K | $0.00 | |
| 2026-02-19 | FENC | FENNEC PHARMACEUTICALS INC. | M — Option exercise | 27.3K | $0.00 | |
| 2026-02-19 | FENC | FENNEC PHARMACEUTICALS INC. | M — Option exercise | 2.5K | $4.08 | $10K |
| 2026-02-02 | FENC | FENNEC PHARMACEUTICALS INC. | A — Grant or award | 1.6K | $0.00 | |
| 2026-01-23 | FENC | FENNEC PHARMACEUTICALS INC. | M — Option exercise | 10.0K | $2.45 | $24K |
| 2026-01-15 | FENC | FENNEC PHARMACEUTICALS INC. | M — Option exercise | 10.0K | $2.45 | $24K |
| 2026-01-07 | FENC | FENNEC PHARMACEUTICALS INC. | M — Option exercise | 14.2K | $2.45 | $35K |
| 2025-09-30 | FENC | FENNEC PHARMACEUTICALS INC. | A — Grant or award | 2.4K | $0.00 | |
| 2025-08-31 | FENC | FENNEC PHARMACEUTICALS INC. | A — Grant or award | 2.4K | $0.00 | |
| 2025-07-31 | FENC | FENNEC PHARMACEUTICALS INC. | A — Grant or award | 2.4K | $0.00 | |
| 2025-06-30 | FENC | FENNEC PHARMACEUTICALS INC. | A — Grant or award | 2.4K | $0.00 | |
| 2025-05-31 | FENC | FENNEC PHARMACEUTICALS INC. | A — Grant or award | 2.4K | $0.00 | |
| 2025-05-22 | FENC | FENNEC PHARMACEUTICALS INC. | M — Option exercise | 8.2K | $5.10 | $42K |
Robert Andrade is the Chief Financial Officer of Fennec Pharmaceuticals Inc., a biopharmaceutical company focused on developing treatments to prevent cisplatin-induced hearing loss in children. He has been involved in multiple SEC filings related to the company's financial activities.…
3 primary Form 4 filings in the last 90 days, covering 1 company.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live Andrade Robert profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.